This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Top Research Reports for Mastercard, Gilead & Goldman Sachs
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Mastercard (MA), Gilead (GILD) and Goldman Sachs (GS).
Why Biotech Stocks Rallied on Biogen's Alzheimer's Test
by Ryan McQueeney
Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.
Biotech Stock Roundup: GILD's Positive CHMP Nod, Regulatory Updates & More
by Zacks Equity Research
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
Is Gilead Sciences a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Gilead Sciences Inc. (GILD) stock is a good choice for value-oriented investors right now from multiple angles.
Novartis to Spin-Off Alcon as Separate Trading Company
by Zacks Equity Research
Novartis announces that it will spin-off its ophthalmology division, Alcon, into a separately-traded standalone company in order to focus on its legacy pharmaceuticals business.
Gilead's (GILD) CAR T Therapy Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead (GILD) obtains positive opinion from the CHMP for its MAA for CAR T therapy, axicabtagene ciloleucel, as a treatment for DLBCL and PMBCL.
4 Biotech Stocks to Bet on in the Second Half of 2018
by Ekta Bagri
While the first half did not turn out to be great for the biotech sector, the second half is expected to be much better. Here, we list four biotechs poised for a good run.
Biotech Stock Roundup: PBYI Soars, MACK Crashes, GILD's Biktarvy Gets EC Nod
by Zacks Equity Research
The biotech sector was in the news with a few hits and misses. Gilead's Biktarvy got approval in Europe while Puma Biotechology is also closer to breast cancer drug approval in Europe.
Gilead's (GILD) Biktarvy Gets EC Nod for HIV- 1 Infection
by Zacks Equity Research
Gilead's (GILD) HIV portfolio gets a further boost with the European Commission's approval of Biktarvy for HIV-1 infection.
CRISPR Science and Stocks: Knowing Enough to Invest
by Kevin Cook
Can you learn enough about the science and the companies to invest with confidence?
Novartis Announces Positive Data on CAR-T Therapy, Kymriah
by Zacks Equity Research
Novartis (NVS) announces positive results on Kymriah from the JULIET TRIAL in patients with relapsed or refractory diffuse large B-cell lymphoma.
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
by Zacks Equity Research
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valeant
NASH Space in Focus as Galmed (GLMD) Posts Positive Data
by Ekta Bagri
Investor focus is back on the NASH space as quite a few companies release promising data on their NASH candidates of late.
Drug Stocks: The Next Hot Industry or Value Traps?
by Tracey Ryniec
These 5 stocks look dirt cheap but is it too good to be true?
Galmed (GLMD) Soars on Positive NASH Data on Aramchol
by Zacks Equity Research
Shares of Galmed Pharmaceuticals (GLMD) surges significantly following positive top-line results on lead candidate Aramchol in NASH patients.
JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space
by Indrajit Bandyopadhyay
Given the growing interest in JAK-inhibitor based treatments, here's a look at some companies that are looking to change the ways to treat autoimmune diseases.
Gilead Collaborates with Hookipa for HBV and HIV Therapies
by Zacks Equity Research
Gilead Sciences (GILD) collaborates with Hookipa Biotech AG for the development of immunization technologies for HBV and HIV diseases.
Biotech Stock Roundup: Regeneron, Celgene, Amgen Impress at ASCO
by Zacks Equity Research
The biotech sector was in focus last week due to the ASCO meet at Chicago where biotech bigwigs presented data on their oncology drugs and promising pipeline candidates.
Madrigal's NASH Study Data Encouraging, Stock Skyrockets
by Zacks Equity Research
Madrigal Pharmaceuticals' (MDGL) thyroid hormone receptor, MGL-3196, achieves significantly sustained reduction in liver fat at week 36 in a phase II study evaluating it in NASH patients.
Gilead & Galapagos Announce Positive Data on Filgotinib
by Zacks Equity Research
Gilead (GILD) and partner Galapagaos (GLPG) announces positive data on filgotinib for the treatment of psoriatic arthritis in adults and ulcerative colitis.
Why Is Gilead Sciences (GILD) Down 7.2% Since Its Last Earnings Report?
by Zacks Equity Research
Gilead Sciences (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: GILD Epclusa's China Approval, BMRN Palynziq's FDA Nod
by Zacks Equity Research
The biotech sector grabbed headlines last week with drug approvals and licensing deals. Investors will await pipeline development news at the ASCO in the coming week.
bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA
by Zacks Equity Research
bluebird (BLUE) obtained Breakthrough Therapy designation from the FDA for Lenti-D for the treatment of patients with cerebral adrenoleukodystrophy, which should expedite its development.
Glaxo and J&J's Two-Drug HIV Regimen Juluca Gets EU Approval
by Zacks Equity Research
Glaxo (GSK) and partner J&J (JNJ) gain marketing approval in the EU for Juluca, a two-drug HIV treatment.
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Lag
by Zacks Equity Research
Intercept's (ICPT) first-quarter results were mixed as loss was narrower than expectations but sales missed expectations. The company also provided Ocaliva sales guidance for 2018.